Disposable Solutions for Biomanufacturing Conference
We bring Disposable Solutions for Biomanufacturing Summit to Europe which will be held on 19th-20th February, 2013 in Brussels, Belgium. The event focuses entirely on the application of single-use technology within manufacturing with studies on extractables and leachables, supply chain reliability, objective cost analysis and innovative case studies.
What last year attendees thought?
- "Provided a vibrant networking platform, as well as informative content on the latest technological and strategic developments across the single use industry" - Arnaud Schmutz, General Manager, Sourcin
- "Good mix of topics. Very good range of relevant subjects with good speaker knowledge" - MSD
- "Excellent mix of speakers & topics. Very valuable" - Pfizer
- "Very valuable" - MSD Biologics UK
Top Reasons to attend the event :
- Latest technological innovations and demonstrations in the latest upstream & downstream product launches all under one roof
- GMP compliance, European & US Regulatory updates, best practice guidelines and analysis on Extractables and leachables
- Insights on Supply chain reliability, Single-use equipment validation and quality control
- New facility design and existing conversion in Bioprocess design and optimisation
- New case studies from leading innovators and CMOs + Online preconference learning with a series of webinar
Expert Speakers Include :
- Vincent Thibon, Senior Analytical Scientist, GlaxoSmithKline
- Arnaud Schmutz, CEO & General Manager, Sourcin
- Doug Ball, Research Fellow, Pfizer
- Tony Hitchcock, Head of Manufacturing Technologies, Cobra Biomanufacturing
The last 10 years has seen a surge in the use of single-use and disposable systems for the production of biopharmaceuticals, initially in early stage products, but increasingly in commercial products. Exclusively revealing the results of a Pharma IQ industry-wide survey, almost a quarter of respondents say their number one goal for 2013 is to move single use systems from development into commercial use, and 45% cited cost savings as the biggest factor for doing so.This Special Report is part of our Pharma Industry Series.